


GUARDIAN™ CONNECT WITH GUARDIAN SENSOR 3 CGM



THE CGM for pregnancy. Get the power to stay in your **healthy glycaemic range**¹ with a Guardian™ Connect CGM through the NDSS.

Always read the instructions for use.



GUARDING WITH MORE ACCURACY AND COMFORT

Guardian Sensor 3, our most **accurate**
and **comfortable** sensor yet.⁵



**LONGER
SENSOR
WEAR TIME
UP TO**

7
DAYS²

**LOW PROFILE,
LIGHTWEIGHT**

35mm
9mm
5.7g



**More flexible sensor
under skin**

**Barrier layer to
improve comfort**


**WATERPROOF
UP TO 2.4M**

for 30 minute periods⁴




**INTELLIGENT
DIAGNOSTICS**

monitors sensor health and
improves performance.³



**SENSOR WORN
ON ABDOMEN
OR BACK OF
UPPER ARM²**



9.4% MARD^{2*}

The Guardian™ Sensor 3 is the
most accurate sensor from Medtronic,
with **greater reliability**.^{2,3,4}


*Guardian Connect, with three to four calibrations per day. Min. 2 calibrations per day required.

GUARDING AGAINST HIGHS AND LOWS



Only Guardian™ Connect can help avoid highs and lows with alerts **up to one hour** before an adverse event.

Primary glycaemic outcome showing HbA1c levels in pregnant women with TD1 using **Medtronic CGM vs. control**¹.



Adapted from Feig DS et al. 2017

PREGNANT WOMEN WITH T1D USING MEDTRONIC CGM DEMONSTRATED:

REDUCTION IN HbA1c LEVELS¹



INCREASED TIME IN TARGET BLOOD GLUCOSE RANGE¹



LESS TIME IN HYPERGLYCAEMIA¹



NO CHANGE IN HYPOGLYCAEMIA¹



FULLY REIMBURSED by the NDSS for eligible patients:

- Women living with type 1 diabetes who are actively planning pregnancy, could be eligible for a maximum of 12 months.
- Once pregnant they will be eligible during the pregnancy and for up to three months after the birth of the child.

For more information visit <https://www.ndss.com.au/type-1-diabetes-and-pregnancy>

GUARDING HEALTH OUTCOMES

**LOWER
INCIDENCE
OF
'LARGE FOR
GESTATIONAL
AGE' INFANTS¹**

**REDUCED
INCIDENCE
OF
MATERNAL
HYPER-
GLYCAEMIA¹**

**FEWER
NEONATAL
INTENSIVE
CARE
ADMISSIONS
FOR >24
HOURS¹**

**AND 1-DAY
SHORTER
HOSPITAL
STAY¹**

The **CONCEPTT** study suggested that *"National and international clinical guideline recommendations in Type 1 Diabetes in pregnancy **should be revised to recommend offering CGM to pregnant women with Type 1 Diabetes** using intensive insulin therapy in the first trimester."*¹

SHARE 24-HOUR SMS ALERTS

with up to five care partners



ACCESS CGM INSIGHTS VIA CARELINK



FREE PERSONAL CGM COACH WITH **STARTRIGHT™**

We provide the service, guidance and answers that people need to better control their diabetes.

To discover how Guardian™ Connect can help women achieve optimal diabetes control during pregnancy¹, speak to your Medtronic representative or visit:

medtronic-diabetes.com.au/guardian-connect

Medtronic

Medtronic Australasia Pty Ltd
2 Alma Road
Macquarie Park, NSW 2113
Australia
Tel: +61 2 9857 9000
Fax: +61 2 9889 5167
Toll Free: 1800 668 670

E-Mail: australia.diabetes@medtronic.com
Facebook: www.facebook.com/MedtronicDiabetesAUS
Instagram: [@medtronicdiabetesaus](https://www.instagram.com/@medtronicdiabetesaus)
YouTube: [Medtronic Diabetes ANZ](https://www.youtube.com/MedtronicDiabetesANZ)

APPROVAL #5926-032019 © Medtronic 2019
All Rights Reserved. Printed in Australia 01/2019

References:

1. Feig DS et al. Lancet 2017; 2017; 390; 10110; 2347-2359
2. Christiansen M et al. Diabetes Technol Ther. 2017; 19(9): 1-11 (when used with Guardian Connect, calibrating three to four times a day, 9.4% MARD)
3. Guardian Sensor 3 Performance Report; 6026113-25A1_A 2016-10
4. Guardian Sensor 3 IFU MMT-7020C1
5. Data on file

hcp.medtronic-diabetes.com.au